Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 3;5(4):34.
doi: 10.3892/mi.2025.233. eCollection 2025 Jul-Aug.

Evaluation of therapeutic response and tolerability to intravenous iron sucrose and ferric carboxymaltose among pregnant women with iron?deficiency anemia: A 6?year experience in a tertiary care center

Affiliations

Evaluation of therapeutic response and tolerability to intravenous iron sucrose and ferric carboxymaltose among pregnant women with iron?deficiency anemia: A 6?year experience in a tertiary care center

Govind R Patel et al. Med Int (Lond). .

Abstract

Iron-deficiency anemia (IDA) is a global health concern in pregnancy associated with adverse fetal and maternal outcomes. The present study aimed to evaluate and compare the therapeutic response and tolerability of intravenous (IV) iron sucrose and ferric carboxymaltose (FCM) administered to pregnant women with IDA. The present prospective observational study was conducted among 334 pregnant women who were in the second or third trimester of pregnancy with moderate to severe IDA and who were treated with IV iron sucrose or FCM at a large tertiary care center between April, 2018 and March, 2024. The therapeutic response was assessed by analyzing the increase in hemoglobin (Hb) and serum ferritin levels at 3 and 6 weeks following the first dose of IV iron treatment. Tolerability was assessed by analyzing the adverse events to drug administration. A statistically significant increase in the mean Hb and serum ferritin levels was observed in both the iron sucrose and FCM groups at 3 and 6 weeks post-infusion (P<0.0001 for all); however, the increase in the FCM group was significantly higher (P<0.0001) than that in the iron sucrose group. Minor temporary adverse drug reactions were comparable (P=0.232) between the both treatment groups, with no major serious adverse events observed in any group. IV iron sucrose and FCM both were efficacious and well tolerated in pregnant women with moderate to severe IDA during the second and third trimester. However, there was an improved overall response to FCM as it caused a greater increase in the Hb and serum ferritin levels than iron sucrose. Therefore, FCM is recommended as an effective and safe alternative to iron sucrose for the treatment of IDA during pregnancy.

Keywords: ferric carboxymaltose; intravenous iron; iron sucrose; iron-deficiency anemia; pregnancy.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no competing interests.

Similar articles

References

    1. Bencaiova G, Burkhardt T, Breymann C. Anemia-prevalence and risk factors in pregnancy. Eur J Intern Med. 2012;23:529–533. - PubMed
    1. Ministry of Health and Family Welfare, Government of India: National Family Health Survey (NFHS-5) 2019-2021, Compendium of fact sheets. Ministry of Health and Family Welfare, Government of India, New Delhi, 2020. https://main.mohfw.gov.in/sites/default/files/NFHS-5_Phase-II_0.pdf. Accessed January 30, 2024.
    1. Young MF, Oaks BM, Tandon S, Martorell R, Dewey KG, Wendt AS. Maternal hemoglobin concentrations across pregnancy and maternal and child health: A systematic review and meta-analysis. Ann N Y Acad Sci. 2019;1450:47–68. doi: 10.1111/nyas.14093. - DOI - PMC - PubMed
    1. Peña-Rosas JP, De-Regil LM, Dowswell T, Viteri FE. Daily oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2012;12(CD004736) doi: 10.1002/14651858.CD004736.pub4. - DOI - PMC - PubMed
    1. Azulay CE, Pariente G, Shoham-Vardi I, Kessous R, Sergienko R, Sheiner E. Maternal anemia during pregnancy and subsequent risk for cardiovascular disease. J Matern Fetal Neonatal Med. 2015;28:1762–1765. doi: 10.3109/14767058.2014.971743. - DOI - PubMed

LinkOut - more resources